Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Bax inhibitor peptide V5 (Synonyms: BIP-V5, BAX Inhibiting Peptide V5)

Name: Bax inhibitor peptide V5
Brand: TargetMol
SKU: T10463
Rating: 4.5 (1 reviews)

Catalog No. T10463 Copy Product Info

🥰Excellent

Bax inhibitor peptide V5 is a cell-penetrating pentapeptide and an inhibitor of Bax-induced apoptosis that specifically inhibits Bax-mediated mitochondria-dependent apoptosis. Bax inhibitor peptide V5 is primarily used in cancer research.

Bax inhibitor peptide V5

Copy Product Info

🥰Excellent

Catalog No. T10463

Synonyms BIP-V5, BAX Inhibiting Peptide V5

Cas No. 579492-81-2

Pack Size	Price	USA Stock	Global Stock
5 mg	$87	7-10 days	7-10 days
10 mg	$126	7-10 days	7-10 days
25 mg	$267	7-10 days	7-10 days
50 mg	$443	7-10 days	7-10 days
100 mg	Inquiry	7-10 days	7-10 days
200 mg	Inquiry	7-10 days	7-10 days

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Liquid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Bax inhibitor peptide V5 is a cell-penetrating pentapeptide and an inhibitor of Bax-induced apoptosis that specifically inhibits Bax-mediated mitochondria-dependent apoptosis. Bax inhibitor peptide V5 is primarily used in cancer research.
In vitro	Methods: Human alveolar epithelial cell line A549 was treated with Bax inhibitor peptide V5 (200 μM). After 1 hour of pretreatment, bleomycin (120 mU/ml) was added, and the cells were incubated for a total of 24 hours. Cell apoptosis was then assessed. Results: Pretreatment with Bax inhibitor peptide V5 significantly inhibited apoptosis in A549 cells and significantly reduced broleomycin-induced activated Bax expression. [1] Method: Isolated mouse islets, dispersed into single cells, were treated with Bax inhibitor peptide V5 (100 μmol/L) and incubated for 24 hours; apoptosis was assessed by flow cytometry. Results: Bax inhibitor peptide V5 significantly reduced the apoptosis rate of mouse islet cells. [2]
In vivo	Methods: To investigate the effects of the Bax inhibitor peptide V5 on bleomycin-induced lung injury, female C57BL/6J mice were used. Bleomycin (2 U/kg) and BIP-V5 (4 μmol/mouse) were administered intratracheally in a single dose (Day 0), and the animals were observed for 14 days. Results: The 14-day cumulative survival rate was 75% in the Bax inhibitor peptide V5 group and 25% in the negative control peptide group, indicating a significant improvement in bleomycin-induced lung injury. [1] Methods: To investigate the effects of Bax inhibitor peptide V5 combined with FGF-2 on early post-transplant islet survival, apoptosis, and inflammatory factors in the early post-transplant period, STZ-induced diabetic Balb/c mice were used. Bax inhibitor peptide V5 (100 μmol/L) and FGF-2 (100 ng) were encapsulated in gelatin microspheres, mixed with islets (150 IEQ), and transplanted subcapsularly into the kidney. PCR was performed 2 days later, and tissue was harvested 3 days later. Results: The Bax inhibitor peptide V5 significantly improved the function of isolated islets in the mouse model and enhanced the function of transplanted islets.[2]
Synonyms	BIP-V5, BAX Inhibiting Peptide V5

Chemical Properties

Molecular Weight	586.79
Formula	C₂₇H₅₀N₆O₆S
Cas No.	579492-81-2
Smiles	C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)CC(C)C)=O)CCSC)(=O)[C@H]1N(C([C@H](C(C)C)N)=O)CCC1
Relative Density.	1.185 g/cm3 (Predicted)
Sequence	H-Val-Pro-Met-Leu-Lys-OH
Sequence Short	VPMLK

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 80 mg/mL (136.33 mM), Sonication is recommended.

DMSO: 80 mg/mL (136.33 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (3.41 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.7042 mL	8.5209 mL	17.0419 mL	85.2094 mL
5 mM	0.3408 mL	1.7042 mL	3.4084 mL	17.0419 mL
10 mM	0.1704 mL	0.8521 mL	1.7042 mL	8.5209 mL
20 mM	0.0852 mL	0.4260 mL	0.8521 mL	4.2605 mL
50 mM	0.0341 mL	0.1704 mL	0.3408 mL	1.7042 mL
100 mM	0.0170 mL	0.0852 mL	0.1704 mL	0.8521 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Citations

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc